Beam Therapeutics Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Beam Therapeutics Inc. (BEAM) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$14.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-04
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.31M, a 86.67% decline year-over-year.
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$16.26M.
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $14.30M.
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.98M.
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $7.68M.
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$57.69M, a 185.25% decline from fiscal 2023.
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $67.66M.
- Beam Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$16.93M, a 138.56% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$14.94M 10-Q · filed 2026-08-04 | -$645.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$16.26M 10-Q · filed 2026-05-07 | -$1.96M derived: sum of 2 quarters · filed 2026-05-07 | $17.00K derived: sum of 3 quarters · filed 2026-05-07 | $9.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.27M derived: sum of 2 quarters · filed 2026-02-24 | $26.14M derived: sum of 3 quarters · filed 2026-08-04 | $7.68M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $11.85M derived: sum of 2 quarters · filed 2026-08-04 | -$6.61M 10-Q · filed 2025-11-04 | -$10.69M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $9.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$8.59M 10-Q · filed 2026-08-04 | -$12.66M derived: sum of 3 quarters · filed 2026-08-04 | -$22.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$18.46M 10-Q · filed 2026-05-07 | -$22.53M derived: sum of 2 quarters · filed 2026-05-07 | -$32.38M derived: sum of 3 quarters · filed 2026-05-07 | -$51.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$13.92M derived: sum of 2 quarters · filed 2026-02-24 | -$33.41M derived: sum of 3 quarters · filed 2026-02-24 | -$57.69M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$9.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$29.34M derived: sum of 2 quarters · filed 2025-11-04 | -$53.61M 10-Q · filed 2025-11-04 | $16.79M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$19.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$43.76M 10-Q · filed 2025-08-05 | $26.64M derived: sum of 3 quarters · filed 2026-02-24 | $34.06M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$24.27M 10-Q · filed 2025-05-06 | $46.13M derived: sum of 2 quarters · filed 2026-02-24 | $53.54M derived: sum of 3 quarters · filed 2026-02-24 | $53.28M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $70.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $77.82M derived: sum of 2 quarters · filed 2026-02-24 | $77.55M derived: sum of 3 quarters · filed 2026-02-24 | $67.66M 10-K · filed 2026-02-24 |
| 2023-09-30 | $7.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.15M derived: sum of 2 quarters · filed 2024-11-05 | -$2.74M 10-Q · filed 2024-11-05 | $5.71M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$266.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$10.15M 10-Q · filed 2024-08-06 | -$1.71M derived: sum of 3 quarters · filed 2025-02-25 | $2.23M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$9.89M 10-Q · filed 2024-05-07 | -$1.45M derived: sum of 2 quarters · filed 2025-02-25 | $2.49M derived: sum of 3 quarters · filed 2025-02-25 | -$10.29M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $8.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $12.38M derived: sum of 2 quarters · filed 2025-02-25 | -$400.00K derived: sum of 3 quarters · filed 2025-02-25 | -$16.93M 10-K · filed 2025-02-25 |
| 2022-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$8.84M derived: sum of 2 quarters · filed 2023-11-08 | -$25.38M 10-Q · filed 2023-11-08 | $15.72M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$12.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$29.31M 10-Q · filed 2023-08-08 | $11.78M derived: sum of 3 quarters · filed 2024-02-27 | $12.95M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$16.53M 10-Q · filed 2023-05-10 | $24.56M derived: sum of 2 quarters · filed 2024-02-27 | $25.73M derived: sum of 3 quarters · filed 2024-02-27 | $31.84M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $41.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $42.27M derived: sum of 2 quarters · filed 2024-02-27 | $48.37M derived: sum of 3 quarters · filed 2024-02-27 | $43.91M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $7.28M derived: sum of 2 quarters · filed 2022-11-07 | $2.82M 10-Q · filed 2022-11-07 | $5.63M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $6.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.65M 10-Q · filed 2022-08-09 | $4.46M derived: sum of 3 quarters · filed 2023-02-28 | $8.92M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$4.46M 10-Q · filed 2022-05-09 | -$1.64M derived: sum of 2 quarters · filed 2023-02-28 | $2.82M derived: sum of 3 quarters · filed 2023-02-28 | $2.20M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $7.27M derived: sum of 2 quarters · filed 2023-02-28 | $6.66M derived: sum of 3 quarters · filed 2023-02-28 | $7.04M 10-K · filed 2023-02-28 |
| 2020-09-30 | $4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $3.84M derived: sum of 2 quarters · filed 2021-11-08 | $4.22M 10-Q · filed 2021-11-08 | $6.42M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$617.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$239.00K 10-Q · filed 2021-08-10 | $1.96M derived: sum of 3 quarters · filed 2022-02-28 | $1.91M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $378.00K 10-Q · filed 2021-05-11 | $2.58M derived: sum of 2 quarters · filed 2022-02-28 | $2.53M derived: sum of 3 quarters · filed 2022-02-28 | $4.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.15M derived: sum of 2 quarters · filed 2022-02-28 | $4.17M derived: sum of 3 quarters · filed 2022-02-28 | $3.57M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.97M derived: sum of 2 quarters · filed 2020-11-10 | $1.37M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $1.42M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$595.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |